Abbott Labs: US Justice Department Probing Depakote Marketing
Abbott said in a regulatory filing that the U.S. Attorney for the Western District of Virginia is seeking to determine whether Abbott's marketing activities violated civil or criminal laws including the Federal False Claims Act, the Food and Drug Cosmetic Act, and the Anti-Kickback Statute "in connection with Medicare and/or Medicaid reimbursement to third parties."
Abbott spokeswoman Adelle Infante said the Abbott Park, Ill., company is cooperating with the investigation, but declined further comment.
A spokesman for the U.S. Attorney in the Western District of Virginia couldn't immediately be reached.
Depakote is approved to treat bipolar disorder and seizures and to prevent migraines. Sales declined 70% to $354 million for the first nine months of 2009 due to generic competition.
Abbott shares fell 22 cents, or 0.4%, to $51.40 in recent trading.
-By Peter Loftus, Dow Jones Newswires; 215-656-8289; peter.loftus@dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/access/al?rnd=eK%2FoC0VnMKIcpQjLj5%2BcGg%3D%3D. You can use this link on the day this article is published and the following day.
Publié le 06 novembre 2009 Copyright © 2009 Dowjones
Partager sur:
